2023-504288-18-00Not yet recruitingPhase 1
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 5 Dec 2023
- Start date
- 26 Feb 2024
- Lead sponsor
- Zhejiang Yaoyuan Biotechnology Co. Ltd.
- Diseases
- Hepatitis B
- EU CT number
- 2023-504288-18-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multiprofile Hospital for Active Treatment Sveta Sofia | Sofiya | Bulgaria | Not yet recruiting |
| Spitalul Clinic Judetean De Urgenta Cluj | Cluj-Napoca | Romania | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.